On Apr. 29, 2021, Pfizer and BioNTech announced they had submitted a variation to the Conditional Marketing Authorization in the European Union (EU) to the European Medicines Agency for the Pfizer-BioNTech vaccine COMIRNATY to request an extension of the indication for use in adolescents 12 to 15 years of age.The companies had already submitted a similar request to the U.S. Food and Drug Administration for the Emergency Use Authorization (EUA) and planned to request additional amendments with other regulatory authorities worldwide.

This submission is based on data from a pivotal Phase 3 clinical trial, which enrolled 2,260 participants aged 12 to 15 years. Topline results from this trial, announced on March 31, 2021, showed a vaccine efficacy of 100% in participants with or without prior SARS-CoV-2 infection and robust antibody responses. In the trial, the vaccine also was generally well tolerated. Participants will continue to be monitored for long-term protection and safety for an additional two years after their second dose.

The Pfizer-BioNTech COVID-19 vaccine, which is based on BioNTech proprietary mRNA technology, was developed by both BioNTech and Pfizer. BioNTech is the Marketing Authorization Holder in the European Union, and the holder of emergency use authorizations or equivalent in the United States (jointly with Pfizer), United Kingdom, Canada and other countries in advance of a planned application for full marketing authorizations in these countries.